Abera Bioscience

Nasal pneumococcal vaccines may offer immunity against multiple serotypes and prevent bacterial colonization before infection occurs.

Abera develops universal pneumococcal vaccines for mucosal delivery, offering broader protection across serotypes.

Abera’s preclinical pipeline focuses on mucosal vaccines targeting infectious diseases and oncology.

Abera’s BERA vaccine platform uses outer membrane vesicle carriers decorated with hundreds of antigens.

Abera explains mucosal vaccines and how they work, including their advantages as nasal spray vaccines and mucosal protection.

Vaccine development progresses through stages, from initial ideas to preclinical studies, manufacturing development, and human clinical trials.

The page examines influenza virus history and future solutions to stop pandemics before global spread.

Abera discusses how faster vaccine development and platform technology are critical for global pandemic preparedness.

Abera Bioscience announced the results of the exercise of its TO2025/2026 series warrants.

Abera Biosciences’ Q2 2026 interim report includes financial highlights, key events, and CEO commentary on the company’s progress.

Abera’s board decided to adopt IFRS accounting standards as part of its ongoing development.

Abera Bioscience reported promising study results comparing its pneumococcal vaccine candidate Ab-01.12 with Prevnar.

Abera Bioscience aims to improve global health by developing scalable mucosal vaccine solutions.

Abera Bioscience provides contact information for inquiries about its technology, research collaborations, and business operations.

Abera Bioscience is a biotech company specializing in next-generation mucosal vaccines using novel platforms.

Abera Bioscience’s CEO Maria Alriksson presents the company’s latest advancements in its pneumococcal vaccine at Aktiespararna’s Life Science Event. The presentation highlights ongoing development milestones and strategic updates for the vaccine program. The session provides insights into Abera’s pipeline and operational progress to investors.

Nov 2026Abera BioscienceNews article

Abera Bioscience, an Uppsala-based biotech firm, secures Dutch regulatory approval to begin its first human clinical trial. The clearance comes from the Central Committee on Research Involving Human Subjects, enabling the company to proceed with testing in the Netherlands.

Nov 2026Nordic Life ScienceNews article

Abera Therapeutics receives approval to begin the first human trial of its nasal spray pneumococcal vaccine AB-0112. The vaccine targets conserved proteins common to all pneumococcal serotypes, addressing a key limitation of existing licensed vaccines. Dutch regulators grant ethics clearance for the trial under the CCMO framework.

Nov 2026Tech TimesNews article

A preclinical study demonstrates that an intranasal pneumococcal vaccine using outer membrane vesicles (OMVs) from Gram-negative bacteria offers broad protection. OMVs act as antigen carriers, presenting pathogen-associated molecular patterns (PAMPs) to strengthen mucosal immunity. Researchers highlight OMVs as a promising platform for next-generation vaccines targeting respiratory infections.

Oct 2026BioWorldNews article